Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Nucala exclusivity biosimilar entry?When does ibrutinib come off patent?When sanofi fulfilled aldurazyme post marketing commitment?Rinvoq for ulcerative colitis?Patente xarelto 2026?
See the DrugPatentWatch profile for neupro
Neupro (rotigotine) entered the Hong Kong market in 2007.
For drug introductions, “entered the market” typically refers to when the product was first authorized/registered and became commercially available in the jurisdiction (rather than when it first began clinical development or when patents were filed).
Information for Hong Kong drug launches is often reported by year in secondary listings; if you need the exact day/month (for example, the registration/approval date), tell me whether you want the approval date or the first sale/launch date, and I can narrow it further.
Other Questions About Neupro :